NICE is unable to make a recommendation on decitabine–cedazuridine (Inaqovi) for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable. This is because Otsuka Pharmaceuticals (UK) did not provide an evidence submission. We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance

  • National Institute for Health and Care Excellence (NICE)